Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease

Zewinger, Stephen; Kleber, Marcus E.; Rohrer, Lucia; Lehmann, Marlene; Triem, Sarah; Jennings, Richard T.; Petrakis, Ioannis; Dressel, Alexander; Lepper, Philipp M.; Scharnagl, Hubert; Ritsch, Andreas; Thorand, Barbara; Heier, Margit; Meisinger, Christa; Gala, Tonia de las Heras; Köenig, Wolfgang; Wagenpfeil, Stefan; Schwedhelm, Edzard; Böger, Rainer H.; Laufs, Ulrich; Eckardstein, Arnold von; Landmesser, Ulf; Lüscher, Thomas F.; Fliser, Danilo; März, Winfried; Meinitzer, Andreas; Speer, Thimoteus

doi:10.1093/eurheartj/ehx118

Cited by 82 publications

(64 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…52 HDL with low SDMA is also associated with lower mortality, which may allow SDMA to be an indicator of biologically effective HDL in CKD patients. 52 It is not clear what causes the change in HDL structure and function, whether it be uremia, accumulation of other compounds, RRT, or other factors.…”

Section: Cholesterolmentioning

confidence: 98%

“…Compared to healthy controls, HDL from ESRD‐HD patients has been shown to be much less effective in cholesterol efflux and regulation of inflammation . High‐density Lipoprotein (HDL) from HD patients also promotes endothelial dysfunction via accumulation of symmetric dimethylarginine (SDMA), which is associated with increased all‐cause and cardiovascular mortality . HDL with low SDMA is also associated with lower mortality, which may allow SDMA to be an indicator of biologically effective HDL in CKD patients .…”

Section: Cardiovascular Changes In Uremic Patientsmentioning

confidence: 99%

“…High‐density Lipoprotein (HDL) from HD patients also promotes endothelial dysfunction via accumulation of symmetric dimethylarginine (SDMA), which is associated with increased all‐cause and cardiovascular mortality . HDL with low SDMA is also associated with lower mortality, which may allow SDMA to be an indicator of biologically effective HDL in CKD patients . It is not clear what causes the change in HDL structure and function, whether it be uremia, accumulation of other compounds, RRT, or other factors.…”

Section: Cardiovascular Changes In Uremic Patientsmentioning

confidence: 99%

See 2 more Smart Citations

Hemodialysis‐induced cardiovascular disease

Ahmadmehrabi

Tang

2018

Seminars in Dialysis

130

View full text Add to dashboard Cite

More than half of all deaths among end stage renal disease (ESRD) patients are due to cardiovascular disease (CVD). Cardiovascular changes secondary to renal dysfunction, including fluid overload, uremic cardiomyopathy, secondary hyperparathyroidism, anemia, altered lipid metabolism, and accumulation of gut microbiota-derived uremic toxins like trimethylamine N-oxidase, contribute to the high risk for CVD in the ESRD population. In addition, conventional hemodialysis (HD) itself poses myocardial stress and injury on the already compromised cardiovascular system in uremic patients. This review will provide an overview of cardiovascular changes in chronic kidney disease and ESRD, a description of reported mechanisms for HD-induced myocardial injury, comparison of HD with other treatment modalities in the context of CVD, and possible management strategies.

show abstract

Section: Cholesterolmentioning

confidence: 98%

Section: Cardiovascular Changes In Uremic Patientsmentioning

confidence: 99%

Section: Cardiovascular Changes In Uremic Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Hemodialysis‐induced cardiovascular disease

Ahmadmehrabi

Tang

2018

Seminars in Dialysis

130

View full text Add to dashboard Cite

show abstract

“…Accumulating evidence suggests that HDL function and composition are found to be altered in the presence of overt cardiovascular disease. As such, the presence of CAD, MI [82], heart failure [83], and stroke [84] have been associated with impaired HDL anti-atherogenic properties (i.e., stimulation of vascular NO production, anti-oxidative and anti-apoptotic potential, and cholesterol efflux capacity) [43,85]. In addition, we cannot forget that clinical trials (particularly phase III) include elderly patients under multiple drug treatments.…”

Section: Impact Of Cardiovascular Risk Factor and Co-morbidities On Hmentioning

confidence: 99%

Advances in HDL: Much More than Lipid Transporters

Ben‐Aicha

Badimon

Vilahur

2020

IJMS

102

View full text Add to dashboard Cite

High Density Lipoprotein (HDL) particles, beyond serving as lipid transporters and playing a key role in reverse cholesterol transport, carry a highly variable number of proteins, micro-RNAs, vitamins, and hormones, which endow them with the ability to mediate a plethora of cellular and molecular mechanisms that promote cardiovascular health. It is becoming increasingly evident, however, that the presence of cardiovascular risk factors and co-morbidities alters HDLs cargo and protective functions. This concept has led to the notion that metrics other than HDL-cholesterol levels, such as HDL functionality and composition, may better capture HDL cardiovascular protection. On the other hand, the potential of HDL as natural delivery carriers has also fostered the design of engineered HDL-mimetics aiming to improve HDL efficacy or as drug-delivery agents with therapeutic potential. In this paper, we first provide an overview of the molecules known to be transported by HDL particles and mainly discuss their functions in the cardiovascular system. Second, we describe the impact of cardiovascular risk factors and co-morbidities on HDL remodeling. Finally, we review the currently developed HDL-based approaches.

show abstract

“…Vice versa, in a preclinical hypercholesterolemia model the reduction of ADMA levels was related to less atherosclerotic lesions [67]. Interestingly, in a study including 3.310 patients undergoing coronary angiography, SDMA was identified as marker of high density lipoprotein (HDL) dysfunction, markedly in patients with renal insufficiency which may implicate another pathophysiologic link between renal disease, SDMA and premature vascular disorders [68]. In the original study by Yoo et al [24] ADMA was moreover found to be positively correlated with homocyst(e)ine.…”

Section: Adma and Sdma In Relation To Vascular Risk Factorsmentioning

confidence: 99%

Arginine Derivatives in Cerebrovascular Diseases: Mechanisms and Clinical Implications

Große

Schwedhelm

Worthmann

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

The amino acid L-arginine serves as substrate for the nitric oxide synthase which is crucial in vascular function and disease. Derivatives of arginine, such as asymmetric (ADMA) and symmetric dimethylarginine (SDMA), are regarded as markers of endothelial dysfunction and have been implicated in vascular disorders. While there is a variety of studies consolidating ADMA as biomarker of cerebrovascular risk, morbidity and mortality, SDMA is currently emerging as an interesting metabolite with distinct characteristics in ischemic stroke. In contrast to dimethylarginines, homoarginine is inversely associated with adverse events and mortality in cerebrovascular diseases and might constitute a modifiable protective risk factor. This review aims to provide an overview of the current evidence for the pathophysiological role of arginine derivatives in cerebrovascular ischemic diseases. We discuss the complex mechanisms of arginine metabolism in health and disease and its potential clinical implications in diverse aspects of ischemic stroke.

show abstract

Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease

Abstract: The data identify SDMA as a marker of HDL dysfunction. These findings highlight on the pivotal role of SDMA accumulation in HDL as a mediator of pre-mature cardiovascular disease in patients with CKD.

Cited by 82 publications

References 38 publications

Hemodialysis‐induced cardiovascular disease

Hemodialysis‐induced cardiovascular disease

Advances in HDL: Much More than Lipid Transporters

Arginine Derivatives in Cerebrovascular Diseases: Mechanisms and Clinical Implications

Contact Info

Product

Resources

About